197 related articles for article (PubMed ID: 17269594)
1. Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study.
Mochizuki T; Naganuma S; Tanaka Y; Iwamoto Y; Ishiguro C; Kawashima Y; Maekawa K; Suda A; Akiba T;
Clin Nephrol; 2007 Jan; 67(1):12-9. PubMed ID: 17269594
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A
Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
[TBL] [Abstract][Full Text] [Related]
3. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients - a randomized study.
Honda H; Koiwa F; Ogata H; Shishido K; Sekiguchi T; Michihata T; Ogawa H; Mukai M; Takahashi K; Suzuki R; Kino K; Kato K; Yamamoto K; Kinugasa E; Akizawa T
Int J Clin Pharmacol Ther; 2014 May; 52(5):360-8. PubMed ID: 24569127
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
Nephron Clin Pract; 2006; 102(1):c1-7. PubMed ID: 16166800
[TBL] [Abstract][Full Text] [Related]
7. [The clinical evaluation of maxacalcitol on therapy for secondary hyperparathyroidism of chronic hemodialysis patients].
Kasai K; Abe R; Wakabayashi M; Nakamura K; Sawatani S; Wakabayashi T
Nihon Jinzo Gakkai Shi; 2002; 44(5):464-70. PubMed ID: 12216479
[TBL] [Abstract][Full Text] [Related]
8. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
Moe S; Wazny LD; Martin JE
Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
Oyama Y; Kazama JJ; Omori K; Higuchi N; Kameda S; Yamamoto S; Ito Y; Maruyama H; Narita I; Gejyo F
Clin Exp Nephrol; 2005 Jun; 9(2):142-7. PubMed ID: 15980949
[TBL] [Abstract][Full Text] [Related]
10. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
11. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
[TBL] [Abstract][Full Text] [Related]
12. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
Ando R; Naito S; Inagaki Y; Hata T; Ishida Y; Chida Y; Takayama M; Tachibana K; Ohtsuka M; Inoue A
Ther Apher Dial; 2005 Feb; 9(1):16-23. PubMed ID: 15828901
[TBL] [Abstract][Full Text] [Related]
13. [Suitable examination intervals for hemodialysis patients with secondary hyperparathyroidism treated with maxacalcitol].
Yamada Y; Kumafuji M; Sodeyama T; Suzawa T; Momose M; Tokoo M
Clin Calcium; 2005 Sep; 15 Suppl 1():144-7. PubMed ID: 16272647
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH;
Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
[TBL] [Abstract][Full Text] [Related]
15. [A case with secondary hyperparathyroidism suggesting the direct suppressive effect of maxacalcitol on osteoblasts].
Shiota J; Tanaka A
Nihon Jinzo Gakkai Shi; 2002; 44(5):471-5. PubMed ID: 12216480
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
Malberti F; Corradi B; Cosci P; Calliada F; Marcelli D; Imbasciati E
Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
[TBL] [Abstract][Full Text] [Related]
17. Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
Kazama JJ; Omori K; Higuchi N; Takahashi N; Ito Y; Maruyama H; Narita I; Cantor TL; Gao P; Gejyo F
Nephrol Dial Transplant; 2004 Apr; 19(4):892-7. PubMed ID: 15031346
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Shoji T; Nakatani S; Kabata D; Mori K; Shintani A; Yoshida H; Takahashi K; Ota K; Fujii H; Ueda S; Nishi S; Nakatani T; Yoshiyama M; Goto K; Hamada T; Imanishi M; Ishimura E; Kagitani S; Kato Y; Kumeda Y; Maekawa K; Matsumura T; Nagayama H; Obi Y; Ohno Y; Sai Y; Sakurai M; Sasaki S; Shidara K; Shoji S; Tsujimoto Y; Yamakawa K; Yasuda H; Yodoi S; Inaba M; Emoto M
Clin J Am Soc Nephrol; 2021 Apr; 16(4):599-612. PubMed ID: 33685864
[TBL] [Abstract][Full Text] [Related]
19. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.
Indridason OS; Quarles LD
Kidney Int; 2000 Jan; 57(1):282-92. PubMed ID: 10620210
[TBL] [Abstract][Full Text] [Related]
20. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.
Ito H; Ogata H; Yamamoto M; Takahashi K; Shishido K; Takahashi J; Taguchi S; Kinugasa E
Clin Nephrol; 2009 Jun; 71(6):660-8. PubMed ID: 19473635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]